貓眼娛樂
Maoyan Entertainment
(1896 HK)
25H1業績點評:線下演出票務成新引擎,積極探索和佈局IP衍生業務
25H1E revenue rose on content boost but profit shrank on short-term factors; live show ticketing a new growth driver
|
買入(維持評級) BUY (maintain)
|
投資要點/Investment Thesis
投資要點/Investment Thesis
事件:
貓眼娛樂2025年上半年實現營收24.72億元,同比提升13.9%,主要系娛樂內容服務所得收益增加。 公司歸母凈利潤實現1.78億元,同比下降37.3%; 經調整凈利潤實現2.35億元,同比下降33.2%。 利潤短期承壓主要系春節檔之後大盤遇冷,參與的部分電影專案票房不及預期,以及演出、IP等業務加大投入。 毛利率由2024年上半年的53.3%降至2025年上半年的37.9%,主要系收益成本較2024年上半年增加5.21億元。
娛樂內容服務:主控發行影片數量創新高
根據國家電影局數據,2025年上半年全國電影總票房實現292.31億元,同比增長22.91%,主要系春節檔頭部影片的帶動。 2025年上半年,公司娛樂內容服務板塊業務實現收入12.09億元,同比提升18.0%,主要系公司主控發行影片數量創新高。 2025年上半年,公司參與宣發/出品的國產影片共29部,進口影片9部; 其中,公司主控發行的影片共計24部,開發的影片共有4部,數量均達歷史同期新高水準。 頭部影片的參與數量和深度維持高位,上半年票房前5部的國產影片,公司參與了其中4部影片的發行/出品。 隨著電影大盤在7月中逐漸回暖,(自7月18日起,全國單日票房已連續30多天保持在1億元以上),公司主控發行/出品的多部暑期檔影片,包括《長安的荔枝》《羅小黑戰記2》《戲台》《浪浪山小妖怪》《奇遇》等陸續上映,多部影片票房表現優異,預計將對下半年的利潤產生貢獻和積極影響。 後續儲備專案包括預計定檔國慶的《刺殺小說家2》《熊貓計劃2》、預計定檔跨年檔的《浪浪人生》(韓寒監製,黃渤主演)、《匿殺》,以及《志願軍3》《即興謀殺》等,有望於2025年後續陸續定檔。
在線娛樂票務:電影票務業務龍頭地位鞏固,線下演出票務成新引擎
2025年上半年,公司在線娛樂票務業務實現收入11.80億元,同比提升12.8%,線下演出GMV高增驅動彈性。 1)在線電影票務:據國家電影局統計,2025年上半年電影票房為292.31億元,觀影人次為6.41億,同比分別增長22.91%和16.89%,國產影片票房佔比為91.2%。 我們認為,2025年3月至6月電影市場頭部影片相應缺失導致大盤票房短期承壓,在後續影片供給及觀影總人次的驅動下,2025年中國電影票房表現仍有較大的提升空間。 2)線下演出票務:根據中國演出行業協會數據,2025年上半年專業劇場、小劇場新空間等劇場類演出16.05萬場,票房收入54.02億元,觀眾人數2055.01萬人次。 我們認為,隨著公司加大投入拓展業務類型,有望進一步增強演出票務業務競爭力。 本地演出方面,2025年上半年公司GMV和覆蓋率持續提升,地方曲藝、休閒展覽及脫口秀等品類GMV同比增長均超80%,併為包括張學友、周杰倫、陳奕迅、林俊傑等多位國內頭部藝人的演出專案提供票務。 境外市場方面,公司服務的演出專案GMV同比增長超過300%,與港澳多家頭部場館達成深度合作, 持續豐富港澳自營平台uutix,並進一步擴展服務至東南亞地區,國際化佈局初顯成效。 我們認為,在線電影票務業務或受大盤影響短期承壓,在線下演出市場供需強勁、活躍度提升的大趨勢下,貓眼娛樂在線下演出票務方面的擴展有望帶來業績彈性。
IP衍生業務:積極探索和佈局IP衍生業務,憑藉宣發能力打通線上線下渠道
截至2025年上半年底,公司已經打造《熊貓計劃》系列、《時間之子》等自有IP,並與《羅小黑戰記2》等影片展開電影宣發+IP衍生品的聯動合作。 我們認為,隨著公司深度參與頭部遊戲IP大電影、國漫IP大電影等專案,IP與電影深度融合,有望持續釋放IP價值。
Maoyan’s heavy blockbuster involvement bore fruit as it distributed or produced 4 of the top 5 Chinese films at the box office in H1. We see live performances emerging as a growth driver, while the company builds up an IP merchandise business with O2O integration. We maintain our BUY call.
The gist: BUY
25H1E results: revenue up 14% yoy on content boost; net profit fell 37%
Content: Maoyan the main distributor for a record number of films in H1
Ticketing: movies segment firmed its lead; live shows gained traction
25H1E results: content business spurred 14% yoy revenue rise; net profit fell 37%
Maoyan Entertainment recently released unaudited 25H1E results:
Top and bottom lines: Revenue arrived at RMB2.47bn in H1E, up 13.9% yoy, mainly driven by entertainment content services; and net profit came to RMB178m, down 37.3% yoy, with adjusted net profit at RMB235m, down 33.2% yoy. Maoyan was under short-term profit pressure due to the post-Chinese New Year downturn, lower-than-expected box-office receipts from some film projects, and heavier investments into the live performance and IP businesses.
Margins: Gross margin declined to 37.9% in 25H1 from 53.3% in 24H1, mainly because of a RMB521m yoy increase in cost of revenue.
Entertainment content: Maoyan the main distributor for a record number of films
25H1: distributed or produced 4 of top 5 movies: Total Chinese box-office revenue amounted to RMB29.23bn in 25H1, up 22.91% yoy, based on data by China Film Administration (CFA), driven mainly by major film releases during the Chinese New Year holiday. Maoyan’s entertainment content services generated RMB1.21bn revenue in 25H1, up 18.0% yoy, as it distributed the most films in its history. The company either promoted or produced 29 Chinese films and 9 imported films in the half-year; being the main distributor for 24 films and the developer as well for 4 films, both numbers setting new records. Its deep involvement in blockbusters bore fruit as Maoyan distributed or produced four of the top five Chinese films at the box office in H1.
25H2E outlook: The Chinese film market began to recover in mid-July as box-office receipts climbed past RMB100m daily over 30 days straight since 18 July. Maoyan was main distributor and producer for many summer releases, including The Lychee Road, The Legend of Hei 2, The Stage, Nobody, and The Adventure. Several did well at the box office and would likely have a healthy impact on H2E profits. Projects in the pipeline include Assassin in Red 2 and Panda Plan 2, which are slated for release during China’s National Day holiday; and Row to Win (produced by Han Han and starring Huang Bo) and The Fire Raven, which are scheduled for New Year’s Eve. The Volunteers: Peace at Last and Her Turn are set to be released in 2025E.
Online ticket sales: movies consolidated segment lead; live shows gained traction
Maoyan’s online entertainment ticketing business generated RMB1.18bn revenue in 25H1, up 12.8% yoy, driven by high growth in live performance GMV:
Movies: Box-office revenue climbed 22.91% yoy to RMB29.23bn in 25H1, according to CFA data, while the number of moviegoers rose 16.89% yoy to 641m. Chinese films accounted for 91.2% of box-office revenue. We believe the lack of blockbusters during March to June 2025 exerted short-term pressure on the Chinese box office. The Chinese box office has ample growth headroom for 2025E, driven by H2 film releases and cinema attendance.
Live performances: China hosted 160,500 theatrical performances in major theaters, small theaters and new performance venues in H1, as ticketing revenue amounted to RMB5.40bn from 20.55m theater-goers, according to China Association of Performing Arts data. As Maoyan invests more to widen its business categories, we expect its competitiveness will increase in live performance ticketing. We look at its market regions:
Mainland of China: As Maoyan expanded coverage of performance arts categories in 25H1, GMV shot up by more than 80% yoy in local folk arts, leisure exhibitions and talk shows. The company also handled concert ticketing for many top Chinese artistes like Jacky Cheung, Jay Chou, and Eason Chan, as well as Taiwan-based Singaporean JJ Lin.
Non-mainland: Maoyan’s international buildout is starting to show results. GMV from live performance shows handled by the company increased more than 300% yoy. It tightened partnerships with many leading venue operators in Hong Kong and Macau, where it beefed up its direct-operation platform UUTix, and also expanded its services to Southeast Asia markets.
Upshot: We reckon Maoyan’s online movie ticket sales underwent short-term pressure amid macro market weakness. Given generally strong supply and demand trends, alongside increasing activity in the live performance market, Maoyan’s live performance ticketing business expansion would increase its total profit elasticity.
IP merchandise business buildup: promotion knowhow drove O2O synergies
By the end of 25H1, Maoyan had developed proprietary IPs such as the Panda Plan series and Endless Journey of Love, even while it collaborated on integrated film promotion and IP merchandise initiatives in projects like The Legend of Hei 2. Through deep involvement in major film adaptations of top-tier game IPs and Chinese animation IPs, we expect IP integration with film productions will unlock more IP value.
投資建議/Investment Ideas
投資建議:考慮到大盤票房短期仍受供給影響,以及公司演出、IP等業務加大投入。 我們預測貓眼娛樂2025-2026年收入為45.62/ 52.93億元(前值分別為52.03/54.99億元),經調整凈利潤為3.48/ 5.07億元(前值分別為6.92/8.40億元),當前市值對應2025年經調整凈利潤P/E 24.5x,維持” 買入評級。
Valuation and risks
Given that the Chinese box office is subject to short-term supply constraints and that Maoyan is investing more into the live performance and IP businesses, we lower our 2025/26E forecasts to revenue of RMB4.56bn/5.29bn (previously RMB5.20bn/5.50bn) and adjusted net profit of RMB348m/507m (previously RMB692m/840m). The stock is currently trading at a 2025 adjusted net profit PE of 24.5x. We maintain our BUY rating.
風險提示:影片票房不及預期、影片進度不及預期、內容監管風險、生成式AI應用落地不及預期。
Risks include: lower film box-office receipts than expected; slower film releases than expected; content regulation risks; and slower implementation of generative AI applications than expected.
Email: research@tfisec.com
TFI research report website:
(pls scan the QR code)
本文件由天風國際證券集團有限公司, 天風國際證券與期貨有限公司(證監會中央編號:BAV573)及天風國際資產管理有限公司(證監會中央編號:ASF056)(合稱“天風國際集團”)編制,所載資料可能以若干假設為基礎,僅供作非商業用途及參考之用途,會因經濟、市場及其他情況而隨時更改而毋須另行通知。任何媒體、網站或個人未經授權不得轉載、連結、轉貼或以其他方式複製發表本檔及任何內容。已獲授權者,在使用本檔或任何內容時必須注明稿件來源於天風國際集團,並承諾遵守相關法例及一切使用的國際慣例,不為任何非法目的或以任何非法方式使用本檔,違者將依法追究相關法律責任。本檔所引用之資料或資料可能得自協力廠商,天風國際集團將盡可能確認資料來源之可靠性,但天風國際集團並不對協力廠商所提供資料或資料之準確性負責。且天風國際集團不會就本檔所載任何資料、預測及/或意見的公平性、準確性、時限性、完整性或正確性,以及任何該等預測及/或意見所依據的基準作出任何明文或暗示的保證、陳述、擔保或承諾而負責或承擔任何法律責任。本檔中如有類似前瞻性陳述之內容,此等內容或陳述不得視為對任何將來表現之保證,且應注意實際情況或發展可能與該等陳述有重大落差。本檔並非及不應被視為邀約、招攬、邀請、建議買賣任何投資產品或投資決策之依據,亦不應被詮釋為專業意見。閱覽本文件的人士或在作出任何投資決策前,應完全瞭解其風險以及有關法律、賦稅及會計的特點及後果,並根據個人的情況決定投資是否切合個人的投資目標,以及能否承擔有關風險,必要時應尋求適當的專業意見。投資涉及風險。敬請投資者注意,證券及投資的價值可升亦可跌,過往的表現不一定可以預示日後的表現。在若干國家,傳閱及分派本檔的方式可能受法律或規例所限制。獲取本檔的人士須知悉及遵守該等限制。

